Clinical trials: Disruptive Behavior Disorder
ADHD
Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD
An 8-week, Open-Label Study to Characterize the Response to Modafinil (85mg Film-Coated Tablet) Treatment at Dosages up to 425mg/Day in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) (With an…
- Trial name
- NCT00228540
- Testing
- Modafinil
- Where
- 39 sites in United States
- Sponsor
- Cephalon
Attention Deficit Disorder With Hyperactivity
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.
- Trial name
- NCT00150592
- Testing
- SPD503 (Guanfacine HCl)
- Volunteers
- 182 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations
This is PART B of a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without CNVs in specific genes implicated in glutamatergic signaling and…
- Trial name
- NCT03609619
- Testing
- AEVI-001
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Attention Deficit Hyperactivity Disorder (ADHD)
PRC-063 in an ADULT Workplace Environment
The primary objective of this study is to assess the time of onset and time course of efficacy over 16 hours of PRC-063 compared to placebo in adults diagnosed with ADHD in a simulated adult workplace environment (AWE) setting…
- Trial name
- NCT02225639
- Testing
- PRC-063 25 mg, PRC-063 35 mg, PRC-063 45 mg
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder, Dyslexia
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
- Trial name
- NCT00607919
- Testing
- Atomoxetine
- Where
- 16 sites in United States
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Dasotraline Pediatric ADHD Study
This is a 6 week efficacy and safety study of Dasotraline in subjects 6 to 12 years old with ADHD.
- Trial name
- NCT02428088
- Testing
- Dasotraline
- Where
- 43 sites in United States
- Volunteers
- 330 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Disorder With Hyperactivity
Compliance Survey of ADHD Medication for Optimal Satisfaction (COSMOS)
The survey is designed to identify non-compliant Attention Deficit Hyperactivity Disorder (ADHD) patients who are currently on Immediate- Released Methylphenidate (IR-MPH) and observe any change in compliance after treating with…
- Trial name
- NCT00460720
- Testing
- Observational treatment compliance survey
- Volunteers
- 591 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
ADHD
Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
ADHD has been associated with persistent deficits in the efficient allocation of attention and supports the notion that regulation of the cholinergic system may improve these cognitive deficits in ADHD.
- Trial name
- NCT01124708
- Testing
- TC-5619-238
- Where
- 16 sites in United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
ADHD, Controls
Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness
This work will assess the reliability of a simple painless test for the effectiveness of the commonly used local anesthetic lidocaine
- Trial name
- NCT03680885
- Testing
- Lidocaine gel, Injected lidocaine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- PhenoSolve, LLC
Attention Deficit Hyperactivity Disorder
Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
The purpose of this study is to evaluate the long-term safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.
- Trial name
- NCT02704390
- Testing
- ORADUR®-Methylphenidate
- Where
- 3 sites in Taiwan
- Volunteers
- 64 people
- Sponsor
- Orient Pharma Co., Ltd.
Attention Deficit Disorder With Hyperactivity
Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.
The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD.
- Trial name
- NCT00152022
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.
- Volunteers
- 412 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years
The objective of this study was to evaluate the plasma amphetamine concentration/time profile of amphetamine extended release oral suspension in children aged 4 to 5 years with attention-deficit/hyperactivity disorder, following…
- Trial name
- NCT03610464
- Testing
- Amphetamine Extended Release Suspension [Dyanavel]
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Trichotillomania
A Study in Patients With Trichotillomania
The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 when dosed for 6 weeks versus placebo in adult patients with moderate to severe Trichotillomania.
- Trial name
- TTM (NCT03797521)
- Testing
- SXC-2023
- Where
- 13 sites in United States
- Volunteers
- 128 people
- Sponsor
- Promentis Pharmaceuticals, Inc.
ADHD
CTx-1301 Comparative Bioavailability Study
The primary purpose of this study is to compare the bioavailability of CTx-1301 (dexmethylphenidate) to the registered listed drug, Focalin XR and to evaluate dose proportionality of CTx-1301.
- Trial name
- NCT04138498
- Testing
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cingulate Therapeutics
ADHD
Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of the study is to evaluate the efficacy of SPD489 compared to placebo in adolescent subjects (13-17 years of age inclusive) with ADHD in the analog classroom setting based on the Permanent Product Measure…
- Trial name
- NCT01274221
- Testing
- SPD489
- Where
- 6 sites in United States
- Sponsor
- Shire
ADHD
A Comparative Study to Evaluate a Novel Algorithm As a Diagnostic Aid for ADHD in Youth Ages 6-17.
This study aims to demonstrate the accuracy of the MT1 algorithm using the MindTension biometric sensor device as a diagnostic aid for healthcare providers in diagnosing ADHD in youth ages ≥ 6 to ≤17 years.
- Trial name
- NCT06728969
- Testing
- MT1 Auditory startle response patterns analysis algorithm, T.O.V.A. Continuous Performance Test
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MindTension
Attention Deficit Disorder With Hyperactivity
A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
The purpose of this study is to document the extent of on-label and off-label use of Methylphenidate (MPH) (Concerta), MPH (Ritalin), Atomoxetine (ATO), and Guanfacine (GFC) in Japan.
- Trial name
- NCT04113551
- Testing
- MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO)
- Where
- United States
- Volunteers
- 17,418 people
- Sponsor
- Janssen Research & Development, LLC
Attention Deficit Disorder With Hyperactivity
Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity Disorder
This study will determine whether the drug betahistine increases focus and causes side effects in people with attention deficit hyperactivity disorder.
- Trial name
- NCT00829881
- Testing
- Betahistine Hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- P2D, Inc.
Attention-deficit Hyperactivity Disorder
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
This is a phase 1b, multicenter, open-label, multiple-dose trial in pediatric subjects (4 - 12 years of age, inclusive) with a confirmed diagnosis of ADHD.
- Trial name
- NCT04786730
- Testing
- Centanafadine
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (process by which JNJ-31001074 is absorbed, distributed, metabolized, and eliminated by the body) after a single dose of JNJ-31001074.
- Trial name
- NCT00890292
- Testing
- JNJ-31001074
- Volunteers
- 18 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.